Advanced search
Publication Cover
Expert Review of Vaccines Volume 12, 2013 - Issue 6
Submit an article Journal homepage
262
Views
29
CrossRef citations to date
0
Altmetric
Review

Recent advances in designing an effective vaccine to prevent cytomegalovirus-associated clinical diseases

Vijayendra Dasari Centre for Immunotherapy and Vaccine Development, Department of Immunology, Queensland Institute of Medical Research, 300 Herston Road, Brisbane, QLD 4006, Australia
,
Corey Smith Centre for Immunotherapy and Vaccine Development, Department of Immunology, Queensland Institute of Medical Research, 300 Herston Road, Brisbane, QLD 4006, Australia
&
Rajiv Khanna Centre for Immunotherapy and Vaccine Development, Department of Immunology, Queensland Institute of Medical Research, 300 Herston Road, Brisbane, QLD 4006, Australia. [email protected]
Pages 661-676 | Published online: 09 Jan 2014

References

  • Ahlfors K, Ivarsson SA, Harris S. Report on a long-term study of maternal and congenital cytomegalovirus infection in Sweden. Review of prospective studies available in the literature. Scand. J. Infect. Dis. 31(5), 443–457 (1999).
  • Boppana SB, Rivera LB, Fowler KB, Mach M, Britt WJ. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N. Engl. J. Med. 344(18), 1366–1371 (2001).
  • Novak Z, Ross SA, Patro RK et al. Cytomegalovirus strain diversity in seropositive women. J. Clin. Microbiol. 46(3), 882–886 (2008).
  • Wang C, Zhang X, Bialek S, Cannon MJ. Attribution of congenital cytomegalovirus infection to primary versus non-primary maternal infection. Clin. Infect. Dis. 52(2), e11–e13 (2011).
  • Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev. Med. Virol. 17(5), 355–363 (2007).
  • Revello MG, Zavattoni M, Furione M, Fabbri E, Gerna G. Preconceptional primary human cytomegalovirus infection and risk of congenital infection. J. Infect. Dis. 193(6), 783–787 (2006).
  • Fowler KB, Stagno S, Pass RF. Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 289(8), 1008–1011 (2003).
  • Yamamoto AY, Mussi-Pinhata MM, Boppana SB et al. Human cytomegalovirus reinfection is associated with intrauterine transmission in a highly cytomegalovirus-immune maternal population. Am. J. Obstet. Gynecol. 202(3), 297.e1–297.e8 (2010).
  • Legendre C, Pascual M. Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences. Clin. Infect. Dis. 46(5), 732–740 (2008).
  • Kotton CN, Kumar D, Caliendo AM et al.; Transplantation Society International CMV Consensus Group. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 89(7), 779–795 (2010).
  • Fishman JA, Emery V, Freeman R et al. Cytomegalovirus in transplantation – challenging the status quo. Clin. Transplant. 21(2), 149–158 (2007).
  • Baldanti F, Lilleri D, Gerna G. Monitoring human cytomegalovirus infection in transplant recipients. J. Clin. Virol. 41(3), 237–241 (2008).
  • Chou SW. Cytomegalovirus infection and reinfection transmitted by heart transplantation. J. Infect. Dis. 155(5), 1054–1056 (1987).
  • Brennan DC. Cytomegalovirus in renal transplantation. J. Am. Soc. Nephrol. 12(4), 848–855 (2001).
  • Boeckh M, Boivin G. Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin. Microbiol. Rev. 11(3), 533–554 (1998).
  • Grahame-Clarke C. Human cytomegalovirus, endothelial function and atherosclerosis. Herpes 12(2), 42–45 (2005).
  • Zhu J, Quyyumi AA, Norman JE, Csako G, Epstein SE. Cytomegalovirus in the pathogenesis of atherosclerosis: the role of inflammation as reflected by elevated C-reactive protein levels. J. Am. Coll. Cardiol. 34(6), 1738–1743 (1999).
  • Samanta M, Harkins L, Klemm K, Britt WJ, Cobbs CS. High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. J. Urol. 170(3), 998–1002 (2003).
  • Baryawno N, Rahbar A, Wolmer-Solberg N et al. Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. J. Clin. Invest. 121(10), 4043–4055 (2011).
  • Cobbs CS, Harkins L, Samanta M et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 62(12), 3347–3350 (2002).
  • Liu R, Moroi M, Yamamoto M et al. Presence and severity of Chlamydia pneumoniae and cytomegalovirus infection in coronary plaques are associated with acute coronary syndromes. Int. Heart J. 47(4), 511–519 (2006).
  • Sorlie PD, Nieto FJ, Adam E, Folsom AR, Shahar E, Massing M. A prospective study of cytomegalovirus, herpes simplex virus 1, and coronary heart disease: the atherosclerosis risk in communities (ARIC) study. Arch. Intern. Med. 160(13), 2027–2032 (2000).
  • Aiello AE, Haan MN, Pierce CM, Simanek AM, Liang J. Persistent infection, inflammation, and functional impairment in older Latinos. J. Gerontol. A Biol. Sci. Med. Sci. 63(6), 610–618 (2008).
  • Pawelec G, Derhovanessian E, Larbi A, Strindhall J, Wikby A. Cytomegalovirus and human immunosenescence. Rev. Med. Virol. 19(1), 47–56 (2009).
  • Jacobson MA, Sinclair E, Bredt B et al. Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients. J. Clin. Virol. 35(3), 332–337 (2006).
  • Bernstein DI, Reap EA, Katen K et al. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 28(2), 484–493 (2009).
  • Zhong J, Khanna R. Ad-gBCMVpoly: A novel chimeric vaccine strategy for human cytomegalovirus-associated diseases. J. Clin. Virol. 46(Suppl. 4), S68–S72 (2009).
  • Wloch MK, Smith LR, Boutsaboualoy S et al. Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J. Infect. Dis. 197(12), 1634–1642 (2008).
  • Frankenberg N, Pepperl-Klindworth S, Meyer RG, Plachter B. Identification of a conserved HLA-A2-restricted decapeptide from the IE1 protein (pUL123) of human cytomegalovirus. Virology 295(2), 208–216 (2002).
  • Drulak MW, Malinoski FJ, Fuller SA et al. Vaccination of seropositive subjects with CHIRON CMV gB subunit vaccine combined with MF59 adjuvant for production of CMV immune globulin. Viral Immunol. 13(1), 49–56 (2000).
  • Plachter B, Sinzger C, Jahn G. Cell types involved in replication and distribution of human cytomegalovirus. Adv. Virus Res. 46, 195–261 (1996).
  • Landolfo S, Gariglio M, Gribaudo G, Lembo D. The human cytomegalovirus. Pharmacol. Ther. 98(3), 269–297 (2003).
  • Sinzger C, Grefte A, Plachter B, Gouw AS, The TH, Jahn G. Fibroblasts, epithelial cells, endothelial cells and smooth muscle cells are major targets of human cytomegalovirus infection in lung and gastrointestinal tissues. J. Gen. Virol. 76(Pt 4), 741–750 (1995).
  • Isaacson MK, Juckem LK, Compton T. Virus entry and innate immune activation. Curr. Top. Microbiol. Immunol. 325, 85–100 (2008).
  • DeFilippis VR, Alvarado D, Sali T, Rothenburg S, Früh K. Human cytomegalovirus induces the interferon response via the DNA sensor ZBP1. J. Virol. 84(1), 585–598 (2010).
  • Paludan SR, Bowie AG, Horan KA, Fitzgerald KA. Recognition of herpesviruses by the innate immune system. Nat. Rev. Immunol. 11(2), 143–154 (2011).
  • Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin. Microbiol. Rev. 22(1), 76–98; Table of Contents (2009).
  • Scalzo AA, Yokoyama WM. Cmv1 and natural killer cell responses to murine cytomegalovirus infection. Curr. Top. Microbiol. Immunol. 321, 101–122 (2008).
  • Bukowski JF, Warner JF, Dennert G, Welsh RM. Adoptive transfer studies demonstrating the antiviral effect of natural killer cells in vivo. J. Exp. Med. 161(1), 40–52 (1985).
  • Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. N. Engl. J. Med. 320(26), 1731–1735 (1989).
  • Yeager AS, Grumet FC, Hafleigh EB, Arvin AM, Bradley JS, Prober CG. Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J. Pediatr. 98(2), 281–287 (1981).
  • Stagno S, Pass RF, Dworsky ME et al. Congenital cytomegalovirus infection: the relative importance of primary and recurrent maternal infection. N. Engl. J. Med. 306(16), 945–949 (1982).
  • Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N. Engl. J. Med. 326(10), 663–667 (1992).
  • Polilli E, Parruti G, D’Arcangelo F et al. Preliminary evaluation of the safety and efficacy of standard intravenous immunoglobulins in pregnant women with primary cytomegalovirus infection. Clin. Vaccine Immunol. 19(12), 1991–1993 (2012).
  • Plotkin SA. Congenital cytomegalovirus infection and its prevention. Clin. Infect. Dis. 38(7), 1038–1039 (2004).
  • Fouts AE, Chan P, Stephan JP, Vandlen R, Feierbach B. Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin. J. Virol. 86(13), 7444–7447 (2012).
  • Ryckman BJ, Chase MC, Johnson DC. HCMV gH/gL/UL128-131 interferes with virus entry into epithelial cells: evidence for cell type-specific receptors. Proc. Natl Acad. Sci. USA 105(37), 14118–14123 (2008).
  • Mach M, Kropff B, Dal Monte P, Britt W. Complex formation by human cytomegalovirus glycoproteins M (gpUL100) and N (gpUL73). J. Virol. 74(24), 11881–11892 (2000).
  • Cui X, Meza BP, Adler SP, McVoy MA. Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 26(45), 5760–5766 (2008).
  • Liu Z, Hergenhahn M, Schmeiser HH, Wogan GN, Hong A, Hollstein M. Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene. Proc. Natl Acad. Sci. USA 101(9), 2963–2968 (2004).
  • Cox AL, Mosbruger T, Mao Q et al. Cellular immune selection with hepatitis C virus persistence in humans. J. Exp. Med. 201(11), 1741–1752 (2005).
  • Sarcinella L, Mazzulli T, Willey B, Humar A. Cytomegalovirus glycoprotein B genotype does not correlate with outcomes in liver transplant patients. J. Clin. Virol. 24(1-2), 99–105 (2002).
  • Baldanti F, Lilleri D, Gerna G. Human cytomegalovirus load measurement and its applications for pre-emptive therapy in patients undergoing hematopoietic stem cell transplantation. Hematol. Oncol. 26(3), 123–130 (2008).
  • Burrows SR, Moss DJ, Khanna R. Understanding human T-cell-mediated immunoregulation through herpesviruses. Immunol. Cell Biol. 89(3), 352–358 (2011).
  • Crough T, Burrows JM, Fazou C, Walker S, Davenport MP, Khanna R. Contemporaneous fluctuations in T cell responses to persistent herpes virus infections. Eur. J. Immunol. 35(1), 139–149 (2005).
  • Elkington R, Walker S, Crough T et al. Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J. Virol. 77(9), 5226–5240 (2003).
  • Khan N, Shariff N, Cobbold M et al. Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J. Immunol. 169(4), 1984–1992 (2002).
  • Manley TJ, Luy L, Jones T, Boeckh M, Mutimer H, Riddell SR. Immune evasion proteins of human cytomegalovirus do not prevent a diverse CD8+ cytotoxic T-cell response in natural infection. Blood 104(4), 1075–1082 (2004).
  • Sylwester AW, Mitchell BL, Edgar JB et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J. Exp. Med. 202(5), 673–685 (2005).
  • Komanduri KV, Viswanathan MN, Wieder ED et al. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat. Med. 4(8), 953–956 (1998).
  • Sester M, Sester U, Gärtner B et al. Sustained high frequencies of specific CD4 T cells restricted to a single persistent virus. J. Virol. 76(8), 3748–3755 (2002).
  • Scheper W, van Dorp S, Kersting S et al. γdT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia. Leukemia doi:10.1038/leu.2012.374 (2013) (Epub ahead of print).
  • Knight A, Madrigal AJ, Grace S et al. The role of Vd2-negative γd T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation. Blood 116(12), 2164–2172 (2010).
  • Meraviglia S, Eberl M, Vermijlen D et al. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin. Exp. Immunol. 161(2), 290–297 (2010).
  • Cavanaugh VJ, Deng Y, Birkenbach MP, Slater JS, Campbell AE. Vigorous innate and virus-specific cytotoxic T-lymphocyte responses to murine cytomegalovirus in the submaxillary salivary gland. J. Virol. 77(3), 1703–1717 (2003).
  • Ninomiya T, Takimoto H, Matsuzaki G et al. Vgamma1+ gammadelta T cells play protective roles at an early phase of murine cytomegalovirus infection through production of interferon-gamma. Immunology 99(2), 187–194 (2000).
  • Willcox CR, Pitard V, Netzer S et al. Cytomegalovirus and tumor stress surveillance by binding of a human γd T cell antigen receptor to endothelial protein C receptor. Nat. Immunol. 13(9), 872–879 (2012).
  • Jacobson MA, Adler SP, Sinclair E et al. A CMV DNA vaccine primes for memory immune responses to live-attenuated CMV (Towne strain). Vaccine 27(10), 1540–1548 (2009).
  • Gonczol E, Plotkin S. Development of a cytomegalovirus vaccine: lessons from recent clinical trials. Expert Opin. Biol. Ther. 1(3), 401–412 (2001).
  • Arvin AM, Fast P, Myers M, Plotkin S, Rabinovich R; National Vaccine Advisory Committee. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin. Infect. Dis. 39(2), 233–239 (2004).
  • Jacobson MA, Sinclair E, Bredt B et al. Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12. Vaccine 24(25), 5311–5319 (2006).
  • Schleiss MR, McVoy MA. Overview of congenitally and perinatally acquired cytomegalovirus infections: recent advances in antiviral therapy. Expert Rev. Anti Infect. Ther. 2(3), 389–403 (2004).
  • Pass RF, Duliegè AM, Boppana S et al. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J. Infect. Dis. 180(4), 970–975 (1999).
  • Frey SE, Harrison C, Pass RF et al. Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine. J. Infect. Dis. 180(5), 1700–1703 (1999).
  • Mitchell DK, Holmes SJ, Burke RL, Duliege AM, Adler SP. Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers. Pediatr. Infect. Dis. J. 21(2), 133–138 (2002).
  • Pass RF, Zhang C, Evans A et al. Vaccine prevention of maternal cytomegalovirus infection. N. Engl. J. Med. 360(12), 1191–1199 (2009).
  • Griffiths PD, Stanton A, McCarrell E et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a Phase 2 randomised placebo-controlled trial. Lancet 377(9773), 1256–1263 (2011).
  • Pass RF. Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant. J. Clin. Virol. 46(Suppl. 4), S73–S76 (2009).
  • Sabbaj S, Pass RF, Goepfert PA, Pichon S. Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women. J. Infect. Dis. 203(11), 1534–1541 (2011).
  • Kharfan-Dabaja MA, Boeckh M, Wilck MB et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, Phase 2 trial. Lancet Infect. Dis. 12(4), 290–299 (2012).
  • Adler SP, Plotkin SA, Gonczol E et al. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J. Infect. Dis. 180(3), 843–846 (1999).
  • Bernstein DI, Schleiss MR, Berencsi K et al. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults. J. Infect. Dis. 185(5), 686–690 (2002).
  • Reap EA, Morris J, Dryga SA et al. Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus. Vaccine 25(42), 7441–7449 (2007).
  • Reap EA, Dryga SA, Morris J et al. Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins. Clin. Vaccine Immunol. 14(6), 748–755 (2007).
  • La Rosa C, Wang Z, Brewer JC et al. Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice. Blood 100(10), 3681–3689 (2002).
  • La Rosa C, Longmate J, Lacey SF et al. Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J. Infect. Dis. 205(8), 1294–1304 (2012).
  • Wang Z, La Rosa C, Maas R et al. Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus. J. Virol. 78(8), 3965–3976 (2004).
  • Wang Z, La Rosa C, Li Z et al. Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1. Vaccine 25(6), 1132–1141 (2007).
  • Yue Y, Wang Z, Abel K et al. Evaluation of recombinant modified vaccinia Ankara virus-based rhesus cytomegalovirus vaccines in rhesus macaques. Med. Microbiol. Immunol. 197(2), 117–123 (2008).
  • Wussow F, Yue Y, Martinez J et al. A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques. J. Virol. 87(3), 1322–1332 (2013).
  • Abel K, Martinez J, Yue Y et al. Vaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques. J. Virol. 85(6), 2878–2890 (2011).
  • Wang Z, Zhou W, Srivastava T et al. A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector. Virology 377(2), 379–390 (2008).
  • Pepperl S, Münster J, Mach M, Harris JR, Plachter B. Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression. J. Virol. 74(13), 6132–6146 (2000).
  • Becke S, Aue S, Thomas D et al. Optimized recombinant dense bodies of human cytomegalovirus efficiently prime virus specific lymphocytes and neutralizing antibodies without the addition of adjuvant. Vaccine 28(38), 6191–6198 (2010).
  • Zhong J, Rist M, Cooper L, Smith C, Khanna R. Induction of pluripotent protective immunity following immunisation with a chimeric vaccine against human cytomegalovirus. PLoS ONE 3(9), e3256 (2008).
  • Zhao P, Ma D, Yan S et al. Towards a novel vaccine against human cytomegalovirus based on a chimeric Ad5F35 adenovirus vector expressing the immunodominant antigenic domain 1 epitope. Intervirology 52(1), 35–42 (2009).
  • Elkington R, Shoukry NH, Walker S et al. Cross-reactive recognition of human and primate cytomegalovirus sequences by human CD4 cytotoxic T lymphocytes specific for glycoprotein B and H. Eur. J. Immunol. 34(11), 3216–3226 (2004).
  • Khan N, Bruton R, Taylor GS et al. Identification of cytomegalovirus-specific cytotoxic T lymphocytes in vitro is greatly enhanced by the use of recombinant virus lacking the US2 to US11 region or modified vaccinia virus Ankara expressing individual viral genes. J. Virol. 79(5), 2869–2879 (2005).
  • MacDonald MR, Li XY, Stenberg RM, Campbell AE, Virgin HW 4th. Mucosal and parenteral vaccination against acute and latent murine cytomegalovirus (MCMV) infection by using an attenuated MCMV mutant. J. Virol. 72(1), 442–451 (1998).
  • Cicin-Sain L, Bubic I, Schnee M et al. Targeted deletion of regions rich in immune-evasive genes from the cytomegalovirus genome as a novel vaccine strategy. J. Virol. 81(24), 13825–13834 (2007).
  • Mohr CA, Cîcîn-Saîn L, Wagner M et al. Engineering of cytomegalovirus genomes for recombinant live herpesvirus vaccines. Int. J. Med. Microbiol. 298(1–2), 115–125 (2008).
  • Cui X, Adler SP, Davison AJ, Smith L, Habib el-SE, McVoy MA. Bacterial artificial chromosome clones of viruses comprising the Towne cytomegalovirus vaccine. J. Biomed. Biotechnol. 2012, 428498 (2012).
  • Macagno A, Bernasconi NL, Vanzetta F et al. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J. Virol. 84(2), 1005–1013 (2010).
  • Fu TM, Wang D, Freed DC et al. Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus. Vaccine 30(52), 7469–7474 (2012).
  • Loomis RJ, Lilja AE, Monroe J et al. Vectored co-delivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies. Vaccine 31(6), 919–926 (2013).
  • Griffiths PD. Burden of disease associated with human cytomegalovirus and prospects for elimination by universal immunisation. Lancet Infect. Dis. 12(10), 790–798 (2012).
  • Sung H, Schleiss MR. Update on the current status of cytomegalovirus vaccines. Expert Rev. Vaccines 9(11), 1303–1314 (2010).
  • Emery VC. Could a vaccine against immune-evading cytomegalovirus become a reality? Expert Rev. Vaccines 10(8), 1109–1111 (2011).
  • Colugnati FA, Staras SA, Dollard SC, Cannon MJ. Incidence of cytomegalovirus infection among the general population and pregnant women in the United States. BMC Infect. Dis. 7, 71 (2007).
  • Griffiths PD, Mclean A, Emery VC. Encouraging prospects for immunisation against primary cytomegalovirus infection. Vaccine 19(11–12), 1356–1362 (2001).
  • Dowdle WR. The principles of disease elimination and eradication. Bull. World Health Organ. 76(Suppl. 2), 22–25 (1998).
  • Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev. Med. Virol. 17(4), 253–276 (2007).
  • Leblanc R. Viral Vectored Vaccines: Regulatory Issues. US Food and Drug Administration, Washington, DC, USA (2009).
  • Lee SW, Markham PF, Coppo MJ et al. Attenuated vaccines can recombine to form virulent field viruses. Science 337(6091), 188 (2012).
  • WHO. WHO Informal Consultation on Characterization and Quality Aspect of Vaccines Based on Live Viral Vectors. WHO, Geneva, Switzerland (2003).
  • Liu MA. Immunologic basis of vaccine vectors. Immunity 33(4), 504–515 (2010).
  • Klein M, Schoppel K, Amvrossiadis N, Mach M. Strain-specific neutralization of human cytomegalovirus isolates by human sera. J. Virol. 73(2), 878–886 (1999).
  • Ishibashi K, Tokumoto T, Tanabe K et al. Association of the outcome of renal transplantation with antibody response to cytomegalovirus strain-specific glycoprotein H epitopes. Clin. Infect. Dis. 45(1), 60–67 (2007).
  • Ross SA, Arora N, Novak Z, Fowler KB, Britt WJ, Boppana SB. Cytomegalovirus reinfections in healthy seroimmune women. J. Infect. Dis. 201(3), 386–389 (2010).
  • Hansen SG, Powers CJ, Richards R et al. Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. Science 328(5974), 102–106 (2010).
  • Nogueira E, Ozaki KS, Tomiyama H, Câmara NO, Granato CF. Clinical correlations of human cytomegalovirus strains and viral load in kidney transplant recipients. Int. Immunopharmacol. 9(1), 26–31 (2009).
  • Roubalová K, Strunecký O, Zufanová S, Procházka B, Vitek A. Genotyping of viral glycoprotein B (gB) in hematopoietic stem cell transplant recipients with active cytomegalovirus infection: analysis of the impact of gB genotypes on the patients’ outcome. Epidemiol. Mikrobiol. Imunol. 59(2), 92–99 (2010).
  • Urban M, Britt W, Mach M. The dominant linear neutralizing antibody-binding site of glycoprotein gp86 of human cytomegalovirus is strain specific. J. Virol. 66(3), 1303–1311 (1992).
  • Boppana SB, Fowler KB, Britt WJ, Stagno S, Pass RF. Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus. Pediatrics 104(1 Pt 1), 55–60 (1999).
  • Dasari V, Smith C, Zhong J, Scott G, Rawlinson W, Khanna R. Recombinant glycoprotein B vaccine formulation with Toll-like receptor 9 agonist and immune-stimulating complex induces specific immunity against multiple strains of cytomegalovirus. J. Gen. Virol. 92(Pt 5), 1021–1031 (2011).
  • Mutwiri G, Gerdts V, van Drunen Littel-van den Hurk S et al. Combination adjuvants: the next generation of adjuvants? Expert Rev. Vaccines 10(1), 95–107 (2011).
  • Querec TD, Akondy RS, Lee EK et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 10(1), 116–125 (2009).
  • Nakaya HI, Wrammert J, Lee EK et al. Systems biology of vaccination for seasonal influenza in humans. Nat. Immunol. 12(8), 786–795 (2011).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.